381 related articles for article (PubMed ID: 19791422)
1. Characteristics, pathogenesis, and novel treatments for multiple myeloma.
San Miguel J
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S1-4. PubMed ID: 19791422
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
Bladé J; Cibeira MT; Rosiñol L
Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition and multiple myeloma.
Kanagasabaphy P; Morgan GJ; Davies FE
Curr Opin Investig Drugs; 2007 Jun; 8(6):447-51. PubMed ID: 17621873
[TBL] [Abstract][Full Text] [Related]
4. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Jagannath S; Dimopoulos MA; Lonial S
Leuk Res; 2010 Sep; 34(9):1111-8. PubMed ID: 20472288
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibition for treatment of multiple myeloma: clinical update.
Stadtmauer EA
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib in multiple myeloma.
Mateos MV; San Miguel JF
Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
Bisping G; Wenning D; Kropff M; Gustavus D; Müller-Tidow C; Stelljes M; Munzert G; Hilberg F; Roth GJ; Stefanic M; Volpert S; Mesters RM; Berdel WE; Kienast J
Clin Cancer Res; 2009 Jan; 15(2):520-31. PubMed ID: 19147757
[TBL] [Abstract][Full Text] [Related]
8. [Proteasome inhibitor bortezomib as an anticancer drug].
Yasui H; Hideshima T
Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
[No Abstract] [Full Text] [Related]
9. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
[TBL] [Abstract][Full Text] [Related]
10. [Clinical implications of bortezomib in frontline treatment of newly-diagnosed multiple myeloma].
Ohashi K
Gan To Kagaku Ryoho; 2008 Jun; 35(6):1029-32. PubMed ID: 18633240
[TBL] [Abstract][Full Text] [Related]
11. The persisting challenge of selective and specific proteasome inhibition.
Groll M; Huber R; Moroder L
J Pept Sci; 2009 Feb; 15(2):58-66. PubMed ID: 19109822
[TBL] [Abstract][Full Text] [Related]
12. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.
Altun M; Galardy PJ; Shringarpure R; Hideshima T; LeBlanc R; Anderson KC; Ploegh HL; Kessler BM
Cancer Res; 2005 Sep; 65(17):7896-901. PubMed ID: 16140960
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.
Hideshima T; Chauhan D; Hayashi T; Akiyama M; Mitsiades N; Mitsiades C; Podar K; Munshi NC; Richardson PG; Anderson KC
Oncogene; 2003 Nov; 22(52):8386-93. PubMed ID: 14627979
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
Anderson KC
Exp Hematol; 2007 Apr; 35(4 Suppl 1):155-62. PubMed ID: 17379101
[TBL] [Abstract][Full Text] [Related]
15. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
Boissy P; Andersen TL; Lund T; Kupisiewicz K; Plesner T; Delaissé JM
Leuk Res; 2008 Nov; 32(11):1661-8. PubMed ID: 18394701
[TBL] [Abstract][Full Text] [Related]
16. Targeting multiple myeloma cells and their bone marrow microenvironment.
Pagnucco G; Cardinale G; Gervasi F
Ann N Y Acad Sci; 2004 Dec; 1028():390-9. PubMed ID: 15650264
[TBL] [Abstract][Full Text] [Related]
17. Molecular profiles of proteasome inhibition in plasma cell dyscrasias.
Mitsiades CS
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S23-7. PubMed ID: 19795532
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib in combination with other therapies for the treatment of multiple myeloma.
Orlowski RZ
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S16-20. PubMed ID: 19791424
[TBL] [Abstract][Full Text] [Related]
19. The proteasome: a worthwhile target for the treatment of solid tumours?
Milano A; Iaffaioli RV; Caponigro F
Eur J Cancer; 2007 May; 43(7):1125-33. PubMed ID: 17379504
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of novel therapeutic targets for multiple myeloma.
Hideshima T; Chauhan D; Richardson P; Anderson KC
J Clin Oncol; 2005 Sep; 23(26):6345-50. PubMed ID: 16155018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
